Stovner LJ, Hagen K, Linde M, Steiner TJ. The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates. J Headache Pain. 2022;23:34.

Article  PubMed  PubMed Central  Google Scholar 

Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38:1–211.

Google Scholar 

Silberstein SD, Lee L, Gandhi K, Fitzgerald T, Bell J, Cohen JM. Health care resource utilization and migraine disability along the migraine continuum among patients treated for migraine. Headache. 2018;58:1579–92.

Article  PubMed  Google Scholar 

Buse DC, Manack AN, Fanning KM, et al. Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention study. Headache. 2012;52:1456–70.

Article  PubMed  Google Scholar 

Bigal ME, Rapoport AM, Lipton RB, Tepper SJ, Sheftell FD. Assessment of migraine disability using the migraine disability assessment (MIDAS) questionnaire: a comparison of chronic migraine with episodic migraine. Headache. 2003;43:336–42.

Article  PubMed  Google Scholar 

Buse DC, Manack A, Serrano D, Turkel C, Lipton RB. Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J Neurol Neurosurg Psychiatry. 2010;81:428–32.

Article  PubMed  CAS  Google Scholar 

Buse DC, Reed ML, Fanning KM, Bostic RC, Lipton RB. Demographics, headache features, and comorbidity profiles in relation to headache frequency in people with migraine: results of the American Migraine Prevalence and Prevention (AMPP) study. Headache. 2020;60:2340–56.

Article  Google Scholar 

Altamura C, Corbelli I, de Tommaso M, et al. Pathophysiological bases of comorbidity in migraine. Front Hum Neurosci. 2021;15:640574.

Article  PubMed  PubMed Central  CAS  Google Scholar 

d’Onofrio F, Barbanti P, Petretta V, et al. Migraine and movement disorders. Neurol Sci. 2012;33(Suppl 1):S55–9.

Article  PubMed  Google Scholar 

Ramos ML, García-Cabo C, Leira R, et al. Comorbidity between idiopathic overactive bladder and chronic migraine. Cephalalgia. 2018;38:581–4.

Article  PubMed  Google Scholar 

Matharu M, Katsarava Z, Buse DC, et al. Characterizing neck pain during headache among people with migraine: multicountry results from the Chronic Migraine Epidemiology and Outcomes—International (CaMEO-I) cross-sectional study. Headache. 2024;64:750–63.

Article  PubMed  Google Scholar 

Gonçalves DA, Camparis CM, Franco AL, Fernandes G, Speciali JG, Bigal ME. How to investigate and treat: migraine in patients with temporomandibular disorders. Curr Pain Headache Rep. 2012;16:359–64.

Article  PubMed  Google Scholar 

Gardiner AR, Bhatia KP, Stamelou M, et al. PRRT2 gene mutations: from paroxysmal dyskinesia to episodic ataxia and hemiplegic migraine. Neurology. 2012;79:2115–21.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Dale RC, Gardiner A, Antony J, Houlden H. Familial PRRT2 mutation with heterogeneous paroxysmal disorders including paroxysmal torticollis and hemiplegic migraine. Dev Med Child Neurol. 2012;54:958–60.

Article  PubMed  Google Scholar 

Baser A, Eliaçık S, Baykam MM, Tan FU. Clinical manifestations of overactive bladder with migraine as a comorbidity: a prospective cross-sectional study. Int Neurourol J. 2020;24:375–81.

Article  PubMed  PubMed Central  Google Scholar 

Altman D, Iliadou AN, Lundholm C, Milsom I, Pedersen NL. Somatic comorbidity in women with overactive bladder syndrome. J Urol. 2016;196:473–7.

Article  PubMed  PubMed Central  Google Scholar 

Botox [package insert]. North Chicago, IL: AbbVie; 2023.

Brin MF, Blitzer A. The pluripotential evolution and journey of Botox (onabotulinumtoxinA). Medicine (Baltimore). 2023;102:e32373.

Article  PubMed  PubMed Central  Google Scholar 

Blumenfeld AM, Stark RJ, Freeman MC, Orejudos A, Manack Adams A. Long-term study of the efficacy and safety of onabotulinumtoxinA for the prevention of chronic migraine: COMPEL study. J Headache Pain. 2018;19:13.

Article  PubMed  PubMed Central  Google Scholar 

Ahmed F, Gaul C, Garcia-Monco JC, Sommer K, Martelletti P. An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study. J Headache Pain. 2019;20:26.

Article  PubMed  PubMed Central  Google Scholar 

Aurora SK, Winner P, Freeman MC, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache. 2011;51:1358–73.

Article  PubMed  Google Scholar 

Khalil M, Zafar HW, Quarshie V, Ahmed F. Prospective analysis of the use of OnabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull, UK. J Headache Pain. 2014;15:54.

Article  PubMed  PubMed Central  Google Scholar 

Grazzi L, Giossi R, Montisano DA, et al. Real-world effectiveness of anti-CGRP monoclonal antibodies compared to onabotulinumtoxinA (RAMO) in chronic migraine: a retrospective, observational, multicenter, cohort study. J Headache Pain. 2024;25:14.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Andreou AP, Trimboli M, Al-Kaisy A, Murphy M, Palmisani S, Fenech C, et al. Prospective real-world analysis of onabotulinumtoxinA in chronic migraine post-National Institute for Health and Care Excellence UK technology appraisal. Eur J Neurol. 2018;25:1069-e83.

Article  PubMed  CAS  Google Scholar 

Winner PK, Sadowsky CH, Martinez WC, Zuniga JA, Poulette A. Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine. Headache. 2012;52:1219–25.

Article  PubMed  Google Scholar 

Dowson AJ, Kilminster SG, Salt R. Clinical profile of botulinum toxin A in patients with chronic headaches and cervical dystonia: a prospective, open-label, longitudinal study conducted in a naturalistic clinical practice setting. Drugs R D. 2008;9:147–58.

Article  PubMed  CAS  Google Scholar 

Kocaman G, Kahraman N, Köseoğlu BG, et al. Evaluation of onabotulinumtoxinA treatment in patients with concomitant chronic migraine and temporomandibular disorders. Noro Psikiyatr Ars. 2018;55:330–6.

PubMed  PubMed Central  Google Scholar 

Rodriguez R, Broner SW, Forde G, et al, editors. Real-world diagnosis of chronic migraine in patients with cervical dystonia analyzed by botulinum neurotoxin treatment exposure: an epidemiologic perspective. Annual Meeting of the International Congress of Parkinson's Disease and Movement Disorders; September 27–October 1, 2024; Philadelphia, PA.

Sarva H, Hillson E, Sadeghi M, Pinsky B, Broner S, editors. Annual real-world diagnosis and health care costs among patients with comorbid cervical dystonia and chronic migraine. Annual Assembly of the American Academy of Physical Medicine and Rehabilitation; November 6–10, 2024; San Diego, CA.

Chiu SY, Patel B, Burns MR, et al. High-dose botulinum toxin therapy: safety, benefit, and endurance of efficacy. Tremor Other Hyperkinet Mov (N Y). 2020;10. https://doi.org/10.7916/tohm.v0.749.

Nuanthaisong U, Abraham N, Goldman HB. Incidence of adverse events after high doses of onabotulinumtoxinA for multiple indications. Urology. 2014;84:1044–8.

Article  PubMed  Google Scholar 

Burch RC, Buse DC, Lipton RB. Migraine: epidemiology, burden, and comorbidity. Neurol Clin. 2019;37:631–49.

Article  PubMed  Google Scholar 

Forde G, Brucker BM, Becker Ifantides K, et al. SYNCHRONIZE: real-world retrospective safety analysis of patients treated with onabotulinumtoxinA for more than one therapeutic indication. Toxins (Basel). 2024;16:420.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Bellows S, Jankovic J. Immunogenicity associated with botulinum toxin treatment. Toxins (Basel). 2019. https://doi.org/10.3390/toxins11090491.

Article  PubMed  PubMed Central  Google Scholar 

Jankovic J, Adler CH, Charles D, et al. Primary results from the cervical dystonia patient registry for observation of onabotulinumtoxina efficacy (CD PROBE). J Neurol Sci. 2015;349:84–93.

Article  PubMed  Google Scholar 

Charles PD, Manack Adams A, Davis T, et al. Neck pain and cervical dystonia: treatment outcomes from CD PROBE (Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy). Pain Pract. 2016;16:1073–82.

Article  PubMed